Cervicitis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 44: Line 44:
*A test of cure is recommended 1 week after the first dose of antimicrobial therapy.
*A test of cure is recommended 1 week after the first dose of antimicrobial therapy.
*If symptoms persist, women should be instructed to return for re-evaluation because women with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months after treatment.
*If symptoms persist, women should be instructed to return for re-evaluation because women with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months after treatment.
===Mycoplasma genitalium cervicitis===
===Trichomonas vaginalis cervicitis===


==References==
==References==

Revision as of 21:58, 23 September 2016

Cervicitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cervicitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cervicitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cervicitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cervicitis medical therapy

CDC on Cervicitis medical therapy

Cervicitis medical therapy in the news

Blogs on Cervicitis medical therapy

Directions to Hospitals Treating Cervicitis

Risk calculators and risk factors for Cervicitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Prince Tano Djan, BSc, MBChB [2]

Overview

Antimicrobial therapy with adequate coverage against C. trachomatis should be provided for women at increased risk for C. trachomatis or if follow-up cannot be ensured and if a relatively insensitive diagnostic test is used in place of NAAT. Patients may also require concomitant therapy against N. gonorrhea". Medical therapies include either azithromycin, doxycycline, or a fluoroquinolone. Treatment of sexual partners is also indicated. Follow-up after completion of antimicrobial therapy regimen is required to evaluate for microbial resistance.[1]

Medical Therapy

  • Antimicrobial therapy with adequate coverage against C. trachomatis should be provided for women at increased risk for C. trachomatis or if follow-up cannot be ensured and if a relatively insensitive diagnostic test is used in place of NAAT.
  • The following patients are at increased risk of C. trachomatis:[2]
  • Age ≥ 25 years
  • New or multiple sex partners
  • Patients who engage in unprotected sex
  • Concomitant therapy for N. gonorrhea (gonococcal cervicitis) is recommended among the following patients:[3]
  • Patients in regions with high incidence of gonococcal infections
  • Patients at high risk of gonococcal infections

Chlamydial Cervicitis

  • Cervicitis, Chlamydial[2]
  • Preferred regimen (1): Azithromycin 1 g PO in a single dose
  • Preferred regimen (2): Doxycycline 100 mg PO bid for 7 days
  • Alternative regimen (1): Erythromycin base 500 mg PO qid for 7 days
  • Alternative regimen (2): Erythromycin ethysuccinate 800 mg PO qid for 7 days
  • Alternative regimen (3): Ofloxacin 300 mg PO bid for 7 days
  • Alternative regimen (4): Levofloxacin 500 mg PO qd for 7 days
  • Alternative regimen (5), pregnancy: Azithromycin 1 g PO in a single dose OR Amoxicillin 500 mg PO tid for 7 days OR Erythromycin base 500 mg PO qid for 7 days OR Erythromycin base 250 mg PO qid for 14 days OR Erythromycin ethysuccinate 800 mg PO qid for 14 days OR Erythromycin ethylsuccinate 400 mg PO qid for 14 days
  • Note (1): A test of cure is recommended 1 week after the first dose of antimicrobial therapy.
  • Note (2): Sexual activity should be withheld for 1 week until the antimicrobial regimen is complete.
  • Note (3): Avoid doxycycline and fluoroquinolones among pregnant women

Gonococcal Cervicitis

  • Cervicitis, Gonococcal[3]
  • Preferred regimen: Cephalosporin IM in a single dose AND (Azithromycin 1 g PO in a single dose OR Doxycycline mg PO bid for 7 days)
  • Alternative regimen, cephalosporin allergic: Azithromycin 2 g PO in a single dose
  • Note (1): A test of cure is recommended 1 week after the first dose of antimicrobial therapy.
  • Note (2): Sexual activity should be withheld for 1 week until the antimicrobial regimen is complete.

Treatment of Sexual Partners

  • Sexual partners should also be treated for the pathogens as listed above.
  • A test of cure is also recommended 1 week after the first dose of antimicrobial therapy.
  • The partner's sexual activity should be withheld for 1 week until the antimicrobial regimen is complete.

Follow-Up

  • A test of cure is recommended 1 week after the first dose of antimicrobial therapy.
  • If symptoms persist, women should be instructed to return for re-evaluation because women with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months after treatment.

Mycoplasma genitalium cervicitis

Trichomonas vaginalis cervicitis

References

  1. Diseases Characterized by Urethritis and Cervicitis. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/std/tg2015/urethritis-and-cervicitis.htm Accessed on July 28, 2016
  2. 2.0 2.1 Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC) (2010). "Sexually transmitted diseases treatment guidelines, 2010". MMWR Recomm Rep. 59 (RR-12): 1–110. PMID 21160459.
  3. 3.0 3.1 Centers for Disease Control and Prevention (CDC) (2012). "Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections". MMWR Morb Mortal Wkly Rep. 61 (31): 590–4. PMID 22874837.


Template:WikiDoc Sources